✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Tazemetostat hydrobromideis the generic ingredient in one branded drug marketed by Epizyme Inc and is included in one NDA. There are twenty-three patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Tazemetostat hydrobromide has three hundred and thirty-six patent family members in thirty-eight countries.
One supplier is listed for this compound.
Recent Clinical Trials for tazemetostat hydrobromide
Identify potential brand extensions & 505(b)(2) entrants
|National Cancer Institute (NCI)||Phase 1|
|National Cancer Institute (NCI)||Phase 1/Phase 2|
|Country||Patent Number||Title||Estimated Expiration|
|Denmark||2825161||See Plans and Pricing|
|Israel||252182||שיטות לטיפול בסרטן (Method for treating cancer)||See Plans and Pricing|
|South Korea||102021642||See Plans and Pricing|
|Mexico||362339||FORMA DE SAL DE UN INHIBIDOR DE HISTONA METILTRANSFERASA HUMANA EZH2. (SALT FORM OF A HUMAN HI STONE METHYLTRANSF ERASE EZH2 INHIBITOR.)||See Plans and Pricing|
|Japan||2018062535||ガンの治療方法 (METHODS OF TREATING CANCER)||See Plans and Pricing|
|Turkey||201904660||See Plans and Pricing|
|Australia||2013331368||Methods of treating cancer||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|